<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129960</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-307</org_study_id>
    <secondary_id>2010-019100-23</secondary_id>
    <nct_id>NCT01129960</nct_id>
  </id_info>
  <brief_title>Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain</brief_title>
  <official_title>A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate
      (ESL) as therapy in subjects with Diabetic Neuropathic Pain (DNP) over a 15 week treatment
      phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic neuropathic pain (DNP) is one of the most common complications of diabetes mellitus.
      It currently affects about 1% of the population but its prevalence is expected to increase in
      coming years (European Medicines Agency 2007) in step with the increase in diabetes mellitus
      prevalence, which is expected to affect 220 million people by 2010

      The clinical development of ESL to treat neuropathic pain is based on its chemical and
      pharmacodynamic relationship to sodium channel blockers, including carbamazepine, which is
      effective for treating some neuropathic pain conditions. Preclinical data supports the
      theoretical background.

      This study will examine the efficacy, safety, tolerability and pharmacokinetics of
      Eslicarbazepine acetate for the treatment of diabetic neuropathic pain.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Endpoint in Mean Pain</measure>
    <time_frame>baseline up to endpoint 15 weeks (3-week titration phase and 12-week treatment maintenance phase)</time_frame>
    <description>Study was prematurely halted. The efficacy analysis was restricted to the primary efficacy variable in the interim analysis population. The intended treatment period, starting on the day of the randomization and ending at the efficacy cut-off date (31st October 2011), was the basis for the efficacy analysis; patients with less than 20 days of study medication were excluded from the analysis, except those with early discontinuation. Primary efficacy variable was the difference between the mean values of 7 daily pain scores preceding the efficacy cut-off date (endpoint mean pain score), and before randomization (baseline mean pain score), respectively. The daily pain scores were based on the morning response to the 11-point Numeric Rating Pain Scale (NRPS) question relating to average pain intensity over the last 24 hours. The NPRS is an 11-point scale from 0-10 [&quot;0&quot; = no pain; &quot;10&quot; = the most intense pain imaginable]</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">332</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Eslicarbazepine acetate 800 mg once daily (QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eslicarbazepine acetate 1200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eslicarbazepine acetate 1600 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eslicarbazepine acetate (BIA 2-093)</intervention_name>
    <description>Tablets will be used.</description>
    <arm_group_label>Eslicarbazepine acetate 800 mg once daily (QD)</arm_group_label>
    <arm_group_label>Eslicarbazepine acetate 1200 mg QD</arm_group_label>
    <arm_group_label>Eslicarbazepine acetate 1600 mg QD</arm_group_label>
    <other_name>Exalief</other_name>
    <other_name>Zebinix</other_name>
    <other_name>BIA 2-093</other_name>
    <other_name>ESL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets will be used.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients aged 18 years or older. Female subjects are of
             nonchildbearing potential, defined as surgical sterilization (hysterectomy or
             bilateral oophorectomy or tubal ligation) or at least 2 years postmenopausal
             (spontaneous amenorrhea for at least 24 months before Visit 1), or if of childbearing
             potential, subjects agree to use a medically acceptable nonhormonal method of
             contraception.

          -  Diagnosis of Type 1 or Type 2 diabetes mellitus.

          -  Pain due to bilateral peripheral polyneuropathy caused by Type 1 or Type 2 diabetes
             mellitus.

          -  Have stable glycemic control, as assessed by the investigator, and have glycosylated
             hemoglobin proportion of less or equal than 11% before randomization.

          -  A mean score between 4.0 and 9.0, inclusive, on the 24 hour average pain intensity
             assessment and Visit 3 (ie, 5 of 7 days, 6 of 8 days, 7 of 9 days, or 7 of 10 days).

          -  Compliance with patient diary completion.

          -  If not used to treat DNP, subjects are permitted to take nonsteroidal anti
             inflammatory drugs and selective serotonin reuptake inhibitors if they were kept on a
             stable dose for 1 month prior to Screening and are foreseen to remain stable
             throughout the study.

          -  Competent and able to freely give own informed consent.

          -  Female subjects of childbearing potential, who are not currently breastfeeding, must
             have a negative serum pregnancy test at Visit 1.

        Exclusion Criteria:

          -  Historical exposure to drugs known to cause neuropathy.

          -  Significant skin lesions (active infection, ulcer, etc).

          -  Peripheral vascular disease with a history of amputation, except amputation of toes.

          -  Known intolerance to ESL or to other carboxamide derivatives (eg, carbamazepine or
             oxcarbazepine) or frequent or severe allergic reactions with multiple medications.

          -  Subjects who previously participated in a clinical study with ESL.

          -  Major psychiatric disorders.

          -  Serious or unstable disease that could compromise participation cause hospitalization
             during the study.

          -  Second or third degree atrioventricular blockade not corrected with a pacemaker or any
             clinically significant abnormality in the 12 lead electrocardiogram as determined by
             the investigator.

          -  Subjects taking the following drug classes and individual drugs are excluded:
             benzodiazepines (except short half life sleep agents), skeletal muscle relaxants,
             orally administered steroids, capsaicin, mexiletine, centrally acting analgesics
             (dextromethorphan, tramadol), opiates, topical lidocaine, anticonvulsants, tricyclic
             antidepressants, and serotonin norepinephrine reuptake inhibitors. These drugs require
             a minimum washout period of at least 5 times the half life and should be tapered
             appropriately using product label instructions as a guide.

          -  Relevant clinical laboratory abnormality that, in the investigator's opinion, can
             compromise the subject's safety.

          -  History of drug abuse or dependence (drug categories defined by DSM IV) within the
             past year, excluding nicotine and caffeine.

          -  Subjects who, in the previous 30 days, received treatment with a drug that had not
             received regulatory approval for any indication at the time of study entry.

          -  History of recurrent epileptic seizures except febrile seizures.

          -  History of severe gastroparesis or gastric bypass surgery.

          -  Neurolytic treatment for DNP.

          -  Injected anesthetics or steroid use within 30 days of Visit 1.

          -  Malignancy within past 2 years.

          -  History of chronic hepatitis B or C within the past 3 months or human immunodeficiency
             virus infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BIAL - Portela &amp; Cª, S.A.</name>
      <address>
        <city>S. Mamede do Coronado</city>
        <zip>4045-457</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>May 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2010</study_first_posted>
  <results_first_submitted>January 10, 2014</results_first_submitted>
  <results_first_submitted_qc>July 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2014</results_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Neuropathic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Fifty nine (59) clinical sites in 10 countries
Study period:
Date of first admission: 2010.12.06 Date of last visit: 2012.04.24</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Esl 1600 mg</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093) mg once daily (QD): Tablets will be used.</description>
        </group>
        <group group_id="P2">
          <title>Esl 1200 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) mg QD: Tablets will be used.</description>
        </group>
        <group group_id="P3">
          <title>Esl 800 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) mg QD: Tablets will be used.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo: Tablets will be used.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="83">One subject was randomized to placebo, but was dispensed in error with an ESL 800 mg kit at DB Visit</participants>
                <participants group_id="P4" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-Treat</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-Protocol</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation of the study by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Esl 1600 mg</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093) mg once daily (QD): Tablets will be used.</description>
        </group>
        <group group_id="B2">
          <title>Esl 1200 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) mg QD: Tablets will be used.</description>
        </group>
        <group group_id="B3">
          <title>Esl 800 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) mg QD: Tablets will be used.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo: Tablets will be used.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="83"/>
            <count group_id="B3" value="83"/>
            <count group_id="B4" value="82"/>
            <count group_id="B5" value="332"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="10.93"/>
                    <measurement group_id="B2" value="59.0" spread="11.38"/>
                    <measurement group_id="B3" value="58.0" spread="13.33"/>
                    <measurement group_id="B4" value="59.5" spread="10.25"/>
                    <measurement group_id="B5" value="58.5" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Endpoint in Mean Pain</title>
        <description>Study was prematurely halted. The efficacy analysis was restricted to the primary efficacy variable in the interim analysis population. The intended treatment period, starting on the day of the randomization and ending at the efficacy cut-off date (31st October 2011), was the basis for the efficacy analysis; patients with less than 20 days of study medication were excluded from the analysis, except those with early discontinuation. Primary efficacy variable was the difference between the mean values of 7 daily pain scores preceding the efficacy cut-off date (endpoint mean pain score), and before randomization (baseline mean pain score), respectively. The daily pain scores were based on the morning response to the 11-point Numeric Rating Pain Scale (NRPS) question relating to average pain intensity over the last 24 hours. The NPRS is an 11-point scale from 0-10 [“0” = no pain; “10” = the most intense pain imaginable]</description>
        <time_frame>baseline up to endpoint 15 weeks (3-week titration phase and 12-week treatment maintenance phase)</time_frame>
        <population>FAS = Full Analysis Set (comprised all randomized subjects with mean pain score at baseline and mean score after randomization; subjects with less than 20 days of study medication of the cut-off date were excluded from the dataset, except those that prematurely withdrew; this was the primary population used in the efficacy analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>Esl 1600 mg</title>
            <description>Eslicarbazepine acetate (Esl) (BIA 2-093) mg once daily (QD): Tablets will be used.</description>
          </group>
          <group group_id="O2">
            <title>Esl 1200 mg</title>
            <description>Eslicarbazepine acetate (BIA 2-093) mg QD: Tablets will be used.</description>
          </group>
          <group group_id="O3">
            <title>Esl 800 mg</title>
            <description>Eslicarbazepine acetate (BIA 2-093) mg QD: Tablets will be used.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo: Tablets will be used.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Mean Pain</title>
          <description>Study was prematurely halted. The efficacy analysis was restricted to the primary efficacy variable in the interim analysis population. The intended treatment period, starting on the day of the randomization and ending at the efficacy cut-off date (31st October 2011), was the basis for the efficacy analysis; patients with less than 20 days of study medication were excluded from the analysis, except those with early discontinuation. Primary efficacy variable was the difference between the mean values of 7 daily pain scores preceding the efficacy cut-off date (endpoint mean pain score), and before randomization (baseline mean pain score), respectively. The daily pain scores were based on the morning response to the 11-point Numeric Rating Pain Scale (NRPS) question relating to average pain intensity over the last 24 hours. The NPRS is an 11-point scale from 0-10 [“0” = no pain; “10” = the most intense pain imaginable]</description>
          <population>FAS = Full Analysis Set (comprised all randomized subjects with mean pain score at baseline and mean score after randomization; subjects with less than 20 days of study medication of the cut-off date were excluded from the dataset, except those that prematurely withdrew; this was the primary population used in the efficacy analysis)</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="0.232"/>
                    <measurement group_id="O2" value="-0.90" spread="0.237"/>
                    <measurement group_id="O3" value="-1.73" spread="0.236"/>
                    <measurement group_id="O4" value="-1.13" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3726</p_value>
            <method>Dunnett's test (analysis of covariance)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8034</p_value>
            <method>Dunnett's test (analysis of covariance)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1391</p_value>
            <method>Dunnett's test (analysis of covariance)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Esl 1600 mg</title>
          <description>Eslicarbazepine acetate (Esl) (BIA 2-093) mg once daily (QD): Tablets will be used.</description>
        </group>
        <group group_id="E2">
          <title>Esl 1200 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) mg QD: Tablets will be used.</description>
        </group>
        <group group_id="E3">
          <title>Esl 800 mg</title>
          <description>Eslicarbazepine acetate (BIA 2-093) mg QD: Tablets will be used.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo: Tablets will be used.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoida haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director R&amp;D</name_or_title>
      <organization>BIAL - Portela &amp; Cª, S.A.</organization>
      <phone>351-22-9866100</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

